Predicine is excited to partner with Canadian Cancer Trials Group (CCTG) and contribute to a European Society for Medical Oncology (ESMO) featured presentation in pancreatic cancer. PredicineATLAS, a 600-gene cfDNA assay, is utilized in the CCTG PA.7 trial to assess the predictive value of blood TMB in metastatic pancreatic ductal adenocarcinoma patients treated with Durvalumab and Tremelimumab, two immunotherapy drugs from AstraZeneca.
Watch the oral presentation at ESMO Virtual Congress 2020.
Presentation ID: LBA65
Title: The Canadian Cancer Trials Group PA.7 Trial: Results of a Randomized Phase II Study of Gemcitabine (GEM) and Nab-Paclitaxel (Nab-P) vs. GEM, Nab-P, Durvalumab (D) and Tremelimumab (T) as First Line Therapy in Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
Speaker: Dr. Daniel Renouf, BC Cancer, University of British Columbia
